---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298958673.md"
description: "Biofrontera shares are trading lower. The company announced that the FDA has approved its sNDA for Ameluz topical gel for the treatment of superficial Basal Cell Carcinoma in adults."
datetime: "2026-09-14T19:05:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298958673.md)
  - [en](https://longbridge.com/en/news/298958673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298958673.md)
generator: "portal-rs"
---

# 

Biofrontera shares are trading lower. The company announced that the FDA has approved its sNDA for Ameluz topical gel for the treatment of superficial Basal Cell Carcinoma in adults.

### Related Stocks

- [BFRI.US](https://longbridge.com/en/quote/BFRI.US.md)
- [BFRIW.US](https://longbridge.com/en/quote/BFRIW.US.md)

## Related News & Research

- [Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma | BFRI Stock News](https://longbridge.com/en/news/298926173.md)
- [Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth | BFRI Stock News](https://longbridge.com/en/news/295802634.md)
- [This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday](https://longbridge.com/en/news/286934092.md)
- [Biotech Stocks At 52-Week Highs - PDEX +18% On FY'26 Results, ODTX +8%, EOLS, BFRI, DRTS](https://longbridge.com/en/news/298251186.md)
- [Biofrontera Reports Q1 2026: Revenue $10.1M, Gross Margin ~80%, Adjusted EBITDA $(3.6) M](https://longbridge.com/en/news/286413013.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**